Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
A Multicenter, Single-Arm, Phase II Study of Mannatide Combined With CAPOX and Tislelizumab as First-Line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
This is a multicenter, open-label, single-arm phase II study evaluating the efficacy and safety of mannatide in combination with CAPOX chemotherapy and tislelizumab as first-line treatment for patients with recurrent or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
Eligible patients will receive oxaliplatin, capecitabine, tislelizumab, and oral mannatide. Tumor response will be assessed according to RECIST version 1.1. Patients without disease progression after induction treatment may continue maintenance therapy with capecitabine, tislelizumab, and mannatide.
The primary objective is to evaluate objective response rate (ORR). Secondary objectives include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), and safety. Exploratory analyses will investigate immune microenvironment changes and potential predictive biomarkers using blood, tumor tissue, and stool samples.
연구 개요
상태
정황
상세 설명
Gastric cancer remains one of the leading causes of cancer-related mortality worldwide. Although immune checkpoint inhibitors combined with chemotherapy have improved outcomes in advanced gastric and gastroesophageal junction adenocarcinoma, many patients still fail to achieve durable responses.
Mannatide is an immunomodulatory agent that has been shown to enhance both innate and adaptive immune responses. Preclinical and clinical studies suggest that mannatide may improve antitumor immunity through activation of macrophages, enhancement of antigen presentation, stimulation of T-cell proliferation, and promotion of natural killer cell activity. These properties provide a rationale for combining mannatide with chemotherapy and immune checkpoint blockade.
This study is a multicenter, open-label, single-arm phase II trial enrolling approximately 52 patients with unresectable recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Participants will receive CAPOX chemotherapy (oxaliplatin plus capecitabine), tislelizumab, and oral mannatide as first-line treatment.
Treatment will be administered for six induction cycles. Tumor assessments will be performed every two cycles according to RECIST version 1.1. Patients without disease progression may continue maintenance therapy consisting of capecitabine, tislelizumab, and mannatide until disease progression, unacceptable toxicity, withdrawal of consent, initiation of another anticancer therapy, death, or completion of the maximum treatment duration.
The primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), and safety. Exploratory endpoints include single-cell RNA sequencing, single-cell T-cell receptor sequencing, multiplex immunofluorescence analysis, and gut microbiome profiling to identify biomarkers associated with treatment response.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Ming Liu, MD
- 전화번호: +8618980606324
- 이메일: liuming629@wchscu.cn
연구 장소
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- West China Hospital of Sichuan University
-
연락하다:
- Ming Liu
- 전화번호: +8618980606324
- 이메일: liuming629@wchscu.cn
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, including signet ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma.
- Unresectable recurrent or metastatic disease confirmed by imaging and surgical evaluation.
- Age 18 to 75 years.
- Expected survival greater than 3 months.
- No prior systemic therapy for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Previous neoadjuvant or adjuvant therapy is allowed if completed at least 6 months before enrollment without evidence of recurrence or progression.
- ECOG performance status 0-1.
- At least one measurable lesion according to RECIST version 1.1.
- Availability of tumor tissue for PD-L1 testing.
- Adequate hematologic, hepatic, renal, and coagulation function.
- Recovery of prior treatment-related toxicities to Grade 0-1 or baseline level.
- Negative pregnancy test for women of childbearing potential and agreement to use effective contraception.
- Ability to understand and willingness to sign informed consent.
Exclusion Criteria:
- HER2-positive gastric or gastroesophageal junction adenocarcinoma.
- Squamous cell carcinoma, undifferentiated carcinoma, or mixed histology.
- Active or uncontrolled central nervous system metastases.
- Uncontrolled pleural effusion, ascites, or clinically significant pericardial effusion.
- Weight loss greater than 20% within 2 months before enrollment.
- Major surgery within 28 days before enrollment.
- Prior anti-PD-1, anti-PD-L1, anti-CTLA-4, or other immune checkpoint inhibitor therapy.
- Active autoimmune disease requiring systemic treatment.
- Active hepatitis B, hepatitis C, or HIV infection.
- Interstitial lung disease or uncontrolled systemic disease.
- Significant cardiovascular disease within 6 months before enrollment.
- Known hypersensitivity to study drugs or their components.
- Participation in another interventional clinical trial within 4 weeks before enrollment.
- History of substance abuse or severe psychiatric disorder.
- History of rheumatic heart disease or known hypersensitivity to mannatide.
- Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: CAPOX + Tislelizumab + Mannatide
Participants will receive CAPOX chemotherapy (oxaliplatin and capecitabine), tislelizumab, and oral mannatide as first-line treatment for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
|
Oxaliplatin 130 mg/m² administered intravenously on Day 1 of each 21-day treatment cycle as part of the CAPOX regimen.
Capecitabine 1000 mg/m² orally twice daily on Days 1-14 of each 21-day treatment cycle.
Tislelizumab 200 mg administered intravenously on Day 1 of each 21-day treatment cycle.
Mannatide 10 mg administered orally three times daily throughout study treatment.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: From treatment initiation until disease progression, assessed every 6 weeks during induction treatment and every 6 to 8 weeks during maintenance treatment, up to 24 months.
|
Objective response rate defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST version 1.1.
|
From treatment initiation until disease progression, assessed every 6 weeks during induction treatment and every 6 to 8 weeks during maintenance treatment, up to 24 months.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
전체 생존(OS)
기간: 최대 24개월
|
최대 24개월
|
|
|
질병 통제율(DCR)
기간: 최대 24개월
|
최대 24개월
|
|
|
Duration of Response (DoR)
기간: Up to 24 months
|
Up to 24 months
|
|
|
Incidence of Adverse Events
기간: From first dose through 30 days after the last dose, up to 24 months.
|
Adverse events assessed according to NCI CTCAE version 5.0.
|
From first dose through 30 days after the last dose, up to 24 months.
|
|
Quality of Life (QoL)
기간: Baseline through completion of study treatment, up to 24 months.
|
Quality of life assessed using the EORTC QLQ-C30 questionnaire.
|
Baseline through completion of study treatment, up to 24 months.
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2025 Review (2538)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .